A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia

Innovations in Clinical Neuroscience

Volumn 8, Issue 8, 2011, Pages 26-33

  Gopal, Srihari ^a   Pandina, Gahan ^a   Lane, Rosanne ^a   Nuamah, Isaac ^a   Remmerie, Bart ^b   Coppola, Danielle ^a   Hough, David ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Acute schizophrenia; Long acting injection; Paliperidone palmitate; Risperidone

Indexed keywords

BENZODIAZEPINE DERIVATIVE; PALIPERIDONE; PLACEBO; RISPERIDONE; SUSTENNA; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ETHNICITY; FEMALE; HUMAN; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT;

EID: 80052873990     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2004;161:1-56.
2. Dixon L, Perkins D, Calmes C. Guideline Watch (September 2009): Practice Guideline for the treatment of Patients with Schizophrenia. Arlington, VA: American Psychiatric Press Inc.; 2009:1-10.
3. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103.
4. Risperdal® Consta® Prescribing Information (last updated December 2010). http://janssencns.com/sites/default/files/pdf/risperdal/risperdalconsta.pdf. Accessed on February 1, 2011.
5. Zyprexa® Relprevv™ Prescribing Information (last updated in December 2010). http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=34272&CFID=17444914&CFTOKEN=c8a3f602998dad37-DB041523-E486-C2E0-26A7061B0512CEEB&jsessionid=ca304a00700781931104. Accessed on May 16, 2011.
6. Invega® Sustenna™ Prescribing Information (last updated in December 2010). http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm215492.htm. Accessed on January 5, 2011.
7. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel oncemonthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48:585-600.
8. Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1022-1031.
9. Gopal S, Hough D, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25:247-256.
10. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebocontrolled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30:235-244.
11. Pandina GJ, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:218-226.
12. Mannaert E, Vermeulen A, Remmerie B, et al. Pharmacokinetic profile of longacting injectable risperidone at steady-state: comparison with oral administration. Encephale. 2005;31:609-615.
13. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101:323-329.
14. Remmerie BM, Sips LL, de Vries R, et al. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;783:461-472.
15. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol. 1998;8:55-66.
16. Gopal S, Gassmann-Mayer C, Palumbo J, et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26:377-387.
17. Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology. 1996;457:35-39.
18. Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Schizophr Res. 2006;81:85-86.
19. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152:173-178.